Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial

ConclusionsThe new phosphate-free formulation of etanercept had statistically significantly lower mean pain scores than the prior formulation, with largest pain reductions observed among patients who reported highest pain with the prior formulation.Trial RegistrationClinicalTrials.gov: NCT02986139.FundingAmgen Inc, Thousand Oaks, CA USA.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research